2025/01/17
SHANGHAI, January 17, 2025 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical and regulatory consulting firm.
NAMSA has agreed to acquire WuXi AppTec’s medical device testing facilities in Minnesota and Georgia. All other WuXi AppTec operations are unchanged, and the company remains committed to providing exceptional service to our customers and helping patients worldwide through our unique integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform.
“This transaction supports our strategic business portfolio optimization, sharpens our focus on and positions us to invest further in our core CRDMO business in the U.S. and elsewhere, and strengthens our unique CRDMO model for pharmaceutical products. It will enhance business synergies across research, development and manufacturing services to better meet the evolving needs of our customers globally,” said Steve Yang, Co-CEO of WuXi AppTec. “Together, we can realize our vision that ‘every drug can be made and every disease can be treated.’”
Both companies will work closely together to ensure a smooth transition for customers and employees.
Advisors
Evercore served as financial advisor, and Wilson Sonsini Goodrich & Rosati acted as legal advisor to WuXi AppTec.
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
About NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry’s trusted partner for successful development and commercialization outcomes. Web: namsa.com